RedHill Biopharma (RDHL) Invested Capital: 2012-2025
Historic Invested Capital for RedHill Biopharma (RDHL) over the last 1 years, with Jun 2025 value amounting to -$418.1 million.
- RedHill Biopharma's Invested Capital fell 1.97% to -$418.1 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$418.1 million, marking a year-over-year decrease of 1.97%. This contributed to the annual value of $7.3 million for FY2024, which is 37.05% down from last year.
- RedHill Biopharma's Invested Capital amounted to -$418.1 million in Q2 2025, which was down 5,800.33% from $7.3 million recorded in Q4 2024.
- Over the past 5 years, RedHill Biopharma's Invested Capital peaked at $92.5 million during Q4 2021, and registered a low of -$418.1 million during Q2 2025.
- Its 3-year average for Invested Capital is -$238.2 million, with a median of -$382.0 million in 2023.
- Data for RedHill Biopharma's Invested Capital shows a maximum YoY slumped of 82.56% (in 2023) over the last 5 years.
- Quarterly analysis of 5 years shows RedHill Biopharma's Invested Capital stood at $92.5 million in 2021, then dropped by 27.76% to $66.8 million in 2022, then plummeted by 82.56% to $11.7 million in 2023, then plummeted by 37.05% to $7.3 million in 2024, then fell by 1.97% to -$418.1 million in 2025.
- Its Invested Capital stands at -$418.1 million for Q2 2025, versus $7.3 million for Q4 2024 and -$410.1 million for Q2 2024.